gutflix
GI learning, personalised

Summary

EFFICACY OF ADALIMUMAB IN PATIENTS WITH PERIANAL CROHN'S DISEASE: A PROSPECTIVE RANDOMIZED TRIAL

Sarah Frota Loiola

UEG Week Copenhagen 2023 | Poster

Colorectal

October 15, 2023

A prospective randomized study of 100 patients with perianal Crohn's disease treated with adalimumab 160/80 mg induction showed 80% remission rate at 3 years, with complete fistula closure assessed by colonoscopy and MRI.

KEY POINTS

- Among 100 patients with perianal fistulizing Crohn's disease (42 with prior infliximab failure, 82 with rectal involvement), remission rates were 18% at week 6, 29% at week 30, 66% at week 52, and 80% (77/96) at 3 years.
- Remission was defined as complete fistula closure confirmed by colonoscopy and MRI.
- All patients received adalimumab 160/80 mg induction; immunosuppressive therapy was stopped at treatment start and steroids tapered after induction.
- Four patients lost response and required temporary loop-ileostomy; no serious adverse events were reported.
- The study was conducted at a reference hospital in Porto Velho, Brazil, from January 2019 to January 2023.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/722b0972-743c-11ee-8db7-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.